Cellectis S.A.
CLLS
Positions held
Your positionsCLLS isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $125.90M | Enterprise value | $4.54M | Trailing P/E | — | Forward P/E | -2.02 |
| PEG | — | Price / book | 2.21 | Beta | 2.91 | Dividend yield | 0.00% |
| Revenue growth | -62.1% | Earnings growth | — | Gross margin | 100.0% | Operating margin | -3.4% |
| Profit margin | -102.3% | ROE | -94.5% | ROA | -11.7% | Debt / equity | 1.96 |
| Current ratio | 1.37 | Free cash flow | $107.70M | Analyst recommendation | none | Mean target | $5.33 |
| 52w high | $5.48 | 52w low | $1.22 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $5.2M | $5.8M | $10.4M | $35.2M | $16.7M |
| Op margin | -449.8% | -435.7% | -166.9% | 22.9% | -57.3% |
| Net income | -$21.8M | -$17.8M | -$26.3M | $0.6M | -$23.7M |
| Gross margin | 55.0% | 59.8% | 71.2% | 93.3% | 85.5% |
| Gross profit | $2.9M | $3.5M | $7.4M | $32.8M | $14.3M |
| Operating income | -$23.5M | -$25.2M | -$17.4M | $8.0M | -$9.6M |
- Revenue -9% vs prior quarter ($5.2M vs $5.8M).
- Gross margin 55% (was 59.8% prior quarter).
- Operating margin compressed to -449.8%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $72.9M | $41.5M | $0.8M | $19.2M | — |
| Op margin | -45.3% | -143.5% | -12887.8% | -467.7% | — |
| Net income | -$67.6M | -$36.8M | -$101M | -$106M | — |
| Gross margin | 86.6% | 77.9% | -882.6% | 55.7% | — |
| Gross profit | $63.2M | $32.3M | -$6.7M | $10.7M | — |
| Operating income | -$33.1M | -$59.6M | -$97.3M | -$89.7M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · European Equities Traded in US as ADRs Fall in Thursday Trading
2026-10-07 · European Equities Traded in US as ADRs Fall in Wednesday Trading
2026-10-06 · Monthly information on share capital and company voting rights
2026-10-06 · European Equities Traded in the US as American Depositary Receipts Track Higher in Tuesday Trading
2026-10-05 · European Equities Traded in the US as American Depositary Receipts Track Lower in Monday Trading
2026-10-02 · European Equities Traded in the US as American Depositary Receipts Track Higher in Friday Trading
2026-10-01 · Cellectis Unveils In Vivo Gene-Editing Plans for Severe Lipid Disorders
2026-09-30 · European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading
2026-09-24 · European Equities Traded in the US as American Depositary Receipts Edge Lower in Thursday Trading
2026-09-23 · European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading
2026-09-22 · European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading
2026-09-21 · European Equities Traded in the US as American depositary Receipts Rise in Monday Trading
Price (daily)
Full chart · RSI · MACD · patterns